BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2015 11:10:00 AM | Browse: 1139 | Download: 2690
 |
Received |
|
2015-05-27 20:41 |
|
Peer-Review Started |
|
2015-05-30 11:49 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2015-06-25 16:47 |
|
Revised |
|
2015-07-22 16:59 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2015-09-02 10:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2015-09-16 18:40 |
|
Articles in Press |
|
2015-09-16 18:40 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-11-03 07:25 |
|
Publish the Manuscript Online |
|
2015-11-23 10:19 |
| ISSN |
1949-8454 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
JAK3 inhibitor Ⅵ is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Naoyuki Nishiya, Yasumitsu Sakamoto, Yusuke Oku, Takamasa Nonaka and Yoshimasa Uehara |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Naoyuki Nishiya, PhD, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan. nnishiya@iwate-med.ac.jp |
| Key Words |
Epidermal growth factor receptor; Tyrosine kinase inhibitor; Gatekeeper mutation; Non-small cell lung cancers |
| Core Tip |
Non-small cell lung cancers caused by mutations in the epidermal growth factor receptor (EGFR) initially respond to tyrosine kinase inhibitors (TKIs). However, the therapeutic efficacy of EGFR-TKIs is limited by drug-resistant mutations such as the gatekeeper mutation T790M. Our present study rediscovered JAK3 inhibitor Ⅵ, a known TKI for Janus kinases (JAKs), as a selective EGFR T790M inhibitor. Our structural analysis revealed similarities among EGFR T790M and JAKs, offering a possible strategy to search for EGFR T790M inhibitors from known kinase inhibitors. Repositioning of the existing therapeutics may facilitate solving clinical problems such as drug resistance and toxicity. |
| Publish Date |
2015-11-23 10:19 |
| Citation |
Nishiya N, Sakamoto Y, Oku Y, Nonaka T, Uehara Y. JAK3 inhibitor Ⅵ is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. World J Biol Chem 2015; 6(4): 409-418 |
| URL |
http://www.wjgnet.com/1949-8454/full/v6/i4/409.htm |
| DOI |
http://dx.doi.org/10.4331/wjbc.v6.i4.409 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
